clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achlorhydria D000126 1 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Adenocarcinoma D000230 166 associated lipids
Angina Pectoris D000787 27 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Bacterial Infections D001424 21 associated lipids
Bacteriuria D001437 7 associated lipids
Barrett Esophagus D001471 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Body Weight D001835 333 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Bradycardia D001919 13 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Bronchitis D001991 6 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Chlamydia Infections D002690 7 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Colitis D003092 69 associated lipids
Confusion D003221 4 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Cross Infection D003428 9 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cysts D003560 4 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatomycoses D003881 17 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diarrhea D003967 32 associated lipids
Diphtheria D004165 2 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenitis D004382 4 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Dyspepsia D004415 5 associated lipids
Dyspnea D004417 10 associated lipids
Ecchymosis D004438 3 associated lipids
Empyema D004653 3 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Endometriosis D004715 29 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Ergotism D004881 4 associated lipids
Erythema Nodosum D004893 5 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Exanthema D005076 11 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Foot Diseases D005534 4 associated lipids
Fractures, Open D005597 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Gastritis D005756 27 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Giardiasis D005873 3 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Hand Dermatoses D006229 5 associated lipids
Hearing Disorders D006311 10 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Heart Failure D006333 36 associated lipids
Hemolysis D006461 131 associated lipids
Hemophilia A D006467 10 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hernia, Hiatal D006551 3 associated lipids
HIV Seropositivity D006679 15 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hypoproteinemia D007019 1 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Influenza, Human D007251 11 associated lipids
Insulin Resistance D007333 99 associated lipids
Iris Diseases D007499 2 associated lipids
Iritis D007500 2 associated lipids
Ischemia D007511 18 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Klebsiella Infections D007710 7 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Leprosy D007918 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Morikawa K et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. 1996 Antimicrob. Agents Chemother. pmid:8726002
Arain TM et al. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. 1996 Antimicrob. Agents Chemother. pmid:8726034
Giacometti A et al. In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. 2005 Antimicrob. Agents Chemother. pmid:16127075
Peric M et al. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. 2003 Antimicrob. Agents Chemother. pmid:12604536
Watanabe K et al. Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. 2004 Antimicrob. Agents Chemother. pmid:15561829
Struillou L et al. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. 1995 Antimicrob. Agents Chemother. pmid:7785988
Kim JM et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. 2004 Antimicrob. Agents Chemother. pmid:15561865
Endo H et al. Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats. 2001 Antimicrob. Agents Chemother. pmid:11709323
Hirschl AM et al. In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori. 2000 Antimicrob. Agents Chemother. pmid:10858365
Alder J et al. Clarithromycin therapy of experimental Treponema pallidum infections in hamsters. 1993 Antimicrob. Agents Chemother. pmid:8494384
Bakker-Woudenberg IA et al. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. 2005 Antimicrob. Agents Chemother. pmid:15917538
Traunmüller F et al. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. 2007 Antimicrob. Agents Chemother. pmid:17606673
Kim YC et al. Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus. 2005 Antimicrob. Agents Chemother. pmid:15917564
Dega H et al. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. 2002 Antimicrob. Agents Chemother. pmid:12234844
Endo H et al. Effects of clarithromycin and amoxicillin on gastric emptying in rats. 2002 Antimicrob. Agents Chemother. pmid:12234874
Roblin PM et al. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. 2010 Antimicrob. Agents Chemother. pmid:20038627
Yasuda H et al. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. 1993 Antimicrob. Agents Chemother. pmid:8239580
Kalach N et al. Clarithromycin resistance and eradication of Helicobacter pylori in children. 2001 Antimicrob. Agents Chemother. pmid:11408237
Hammerschlag MR et al. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1324650
Mor N and Heifets L Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. 1993 Antimicrob. Agents Chemother. pmid:8328792
Nagashima A et al. Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. 2016 Antimicrob. Agents Chemother. pmid:27550358
Rastogi N et al. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. 1991 Antimicrob. Agents Chemother. pmid:1667250
Riska PF et al. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. 2004 Antimicrob. Agents Chemother. pmid:15328134
Perronne C et al. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. 1990 Antimicrob. Agents Chemother. pmid:2171421
Goldstein EJ et al. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. 1999 Antimicrob. Agents Chemother. pmid:10543769
Fernández-Roblas R et al. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. 2000 Antimicrob. Agents Chemother. pmid:10602744
Jung R et al. Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes. 2000 Antimicrob. Agents Chemother. pmid:10681358
Kohno Y et al. Autobacteriographic studies of clarithromycin and erythromycin in mice. 1990 Antimicrob. Agents Chemother. pmid:2140497
Loreto ES et al. New insights into the in vitro susceptibility of Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25223997
Lounis N et al. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. 1997 Antimicrob. Agents Chemother. pmid:9145892
Clark C et al. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. 2002 Antimicrob. Agents Chemother. pmid:12183253
Osborne CS et al. In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. 2009 Antimicrob. Agents Chemother. pmid:19596876
Cavalieri SJ et al. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. 1995 Antimicrob. Agents Chemother. pmid:7492101
Hunt Gerardo S et al. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. 1996 Antimicrob. Agents Chemother. pmid:8891154
Lemaire S et al. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. 2009 Antimicrob. Agents Chemother. pmid:19564365
Steele-Moore L et al. In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. 1999 Antimicrob. Agents Chemother. pmid:10383373
Tamaoki J et al. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. 1995 Antimicrob. Agents Chemother. pmid:7486901
Fernandes PB et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. 1989 Antimicrob. Agents Chemother. pmid:2530933
Leuthner KD et al. Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae. 2006 Antimicrob. Agents Chemother. pmid:16436754
Zhou Z et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China. 2015 Antimicrob. Agents Chemother. pmid:25451048
Gikas A et al. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9756789
Debets-Ossenkopp YJ et al. Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9756790
Kuo CC et al. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8913488
Hogan PA and Sheehan DJ Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. 1998 Antimicrob. Agents Chemother. pmid:9835536
Diacon AH et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. 2012 Antimicrob. Agents Chemother. pmid:22391540
Cirioni O et al. Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. 2008 Antimicrob. Agents Chemother. pmid:18779356
Rouse MS et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. 1997 Antimicrob. Agents Chemother. pmid:9257739
Cynamon MH et al. Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. 2000 Antimicrob. Agents Chemother. pmid:10991883
Pryjma M et al. Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. 2017 Antimicrob. Agents Chemother. pmid:28874379
Bolhuis MS et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. 2013 Antimicrob. Agents Chemother. pmid:23689722
Spaniol V et al. Moraxella catarrhalis AcrAB-OprM efflux pump contributes to antimicrobial resistance and is enhanced during cold shock response. 2015 Antimicrob. Agents Chemother. pmid:25583725
Conte JE et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. 1995 Antimicrob. Agents Chemother. pmid:7726492
Amsden GW et al. Oral cimetidine prolongs clarithromycin absorption. 1998 Antimicrob. Agents Chemother. pmid:9660986
Matic V et al. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. 2004 Antimicrob. Agents Chemother. pmid:15504828
Visalli MA et al. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. 1997 Antimicrob. Agents Chemother. pmid:9303375
Spyridaki A et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. 2012 Antimicrob. Agents Chemother. pmid:22564837
Ednie LM et al. Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). 1997 Antimicrob. Agents Chemother. pmid:9303406
Seyama S et al. Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. 2016 Antimicrob. Agents Chemother. pmid:26953210
Berry V et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. 1998 Antimicrob. Agents Chemother. pmid:9835514
Furuie H et al. Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. 2010 Antimicrob. Agents Chemother. pmid:19933801
Chu SY et al. Absolute bioavailability of clarithromycin after oral administration in humans. 1992 Antimicrob. Agents Chemother. pmid:1387301
Yajko DM et al. Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. 1992 Antimicrob. Agents Chemother. pmid:1387302
de Lalla F et al. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. 1992 Antimicrob. Agents Chemother. pmid:1387303
Zhanel GG et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. 2008 Antimicrob. Agents Chemother. pmid:18285482
Hardy RD et al. Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. 2003 Antimicrob. Agents Chemother. pmid:12709330
Tomioka H et al. Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. 2002 Antimicrob. Agents Chemother. pmid:11796367
Ramón-García S et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. 2011 Antimicrob. Agents Chemother. pmid:21576426
Naik S and Ruck R In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. 1989 Antimicrob. Agents Chemother. pmid:2817858
Phillips RO et al. Reply to "compliance with antimicrobial therapy for buruli ulcer". 2014 Antimicrob. Agents Chemother. pmid:25225343
Klis S et al. Compliance with antimicrobial therapy for buruli ulcer. 2014 Antimicrob. Agents Chemother. pmid:25225342
Tsay FW et al. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. 2017 Antimicrob. Agents Chemother. pmid:28807915
Atkinson BA et al. Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. 1995 Antimicrob. Agents Chemother. pmid:8619588
Bermudez LE et al. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. 1998 Antimicrob. Agents Chemother. pmid:9449283
Andini N and Nash KA Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. 2006 Antimicrob. Agents Chemother. pmid:16801446
Hsu PI et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. 2014 Antimicrob. Agents Chemother. pmid:25070099
van Doorn LJ et al. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. 2001 Antimicrob. Agents Chemother. pmid:11302817
Cheng KL et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. 1998 Antimicrob. Agents Chemother. pmid:9559810
Piccolomini R et al. In vitro activity of clarithromycin against intracellular Helicobacter pylori. 2001 Antimicrob. Agents Chemother. pmid:11302831
Carr RA et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. 1998 Antimicrob. Agents Chemother. pmid:9593146
Sörberg M et al. Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9593154
Derouin F et al. Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. 1992 Antimicrob. Agents Chemother. pmid:1482160
Mougari F et al. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. 2017 Antimicrob. Agents Chemother. pmid:27799212
Yamaguchi H et al. Chlamydia pneumoniae resists antibiotics in lymphocytes. 2003 Antimicrob. Agents Chemother. pmid:12760877
Ji B et al. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. 1996 Antimicrob. Agents Chemother. pmid:8834886
Kutlin A et al. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. 2002 Antimicrob. Agents Chemother. pmid:11796350
Yamamoto T et al. Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. 1996 Antimicrob. Agents Chemother. pmid:8834892
Jacks SS et al. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. 2003 Antimicrob. Agents Chemother. pmid:12709351
Ji B et al. How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? 1996 Antimicrob. Agents Chemother. pmid:8834894
Giamarellos-Bourboulis EJ et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. 2004 Antimicrob. Agents Chemother. pmid:14693524
Alffenaar JW et al. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. 2010 Antimicrob. Agents Chemother. pmid:20585115
Kishii K et al. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. 2010 Antimicrob. Agents Chemother. pmid:20585130
Hoffman HL et al. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. 2003 Antimicrob. Agents Chemother. pmid:12543686
Walker KJ et al. Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. 1994 Antimicrob. Agents Chemother. pmid:7811010
Meyer JM et al. In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9210696
Liu KY et al. Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. 2014 Antimicrob. Agents Chemother. pmid:24687504
Chen D et al. Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. 2017 Antimicrob. Agents Chemother. pmid:28167563
Fontana C et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. 2002 Antimicrob. Agents Chemother. pmid:12435674
Noreddin AM et al. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. 2002 Antimicrob. Agents Chemother. pmid:12435719
Obregón-Henao A et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. 2015 Antimicrob. Agents Chemother. pmid:26303795
Patel KB et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891147